healio.com
Cure8 news brief
Why This Matters
A new FDA approval means another biologic option for people with moderately to severely active Crohn’s disease, including patients who have failed or not tolerated prior therapies.
More IL‑23p19 drugs entering the market could affect treatment choices, insurance coverage, and potentially pricing or sequencing of biologics.
Who Should Pay Attention
Adults with Crohn’s disease, patients who have tried or are considering biologics, IBD clinicians, and researchers following IL‑23 targeted therapies.
Study Snapshot
Story typeResearch news
Evidence typeRegulatory update
Source depthFull source text
What To Know
The FDA approved Omvoh (mirikizumab‑mrkz) for moderately to severely active Crohn’s disease based on data from the 52‑week phase 3 VIVID‑1 trial and ongoing VIVID‑2 extension results.
Healio reports this makes mirikizumab the second IL‑23p19–specific inhibitor approved for both major IBD types, joining risankizumab (Skyrizi) and alongside IL‑12/23 inhibitor ustekinumab; guselkumab (Tremfya) is awaiting approval for Crohn’s disease.
Trial results cited include higher rates of 1‑year clinical remission and endoscopic response with Omvoh versus placebo, and safety findings similar to its ulcerative colitis experience with listed common adverse reactions and label warnings.
Keep In Mind
This is a regulatory approval story based on phase 3 trial results (VIVID‑1) and extension data (VIVID‑2) reported by the sponsor and Healio. The article summarizes trial endpoints (clinical remission by CDAI, endoscopic response) and safety signals but does not replace reading the original FDA label or peer‑reviewed publications.
Real‑world effectiveness, head‑to‑head comparisons among IL‑23 agents, long‑term safety, and effects on cost and access remain to be fully established.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationhealio.com
Indexed viaBing News
Source typeResearch news
PublishedJan 16, 2025, 8:53 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Lilly nets a second FDA okay for Omvoh, in Crohn's disease
A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...
J&J adds to IL-23 options in Crohn's after FDA approval
A newly FDA‑approved IL‑23 drug for Crohn’s may increase treatment options for people with IBD, including an IV and a subcutaneous formulation. The approval could affect switching decisions for patients not responding to...
Lilly’s I&I Push Gains Momentum With Omvoh Expansion
An FDA approval means another biologic option is available for Crohn’s disease, which could affect treatment choices and insurance coverage. The approval also signals pharma competition and pipeline activity that may...